Application for registration and marketing authorization of quadrivalent influenza vaccine has been accepted
January 30, 2025
Source: drugdu
36
Chengda Bio announced in the evening that the application for registration and marketing authorization of the quadrivalent influenza virus split vaccine (referred to as "quadrivalent influenza vaccine") developed by its wholly-owned subsidiary Chengda Bio (Benxi) Co., Ltd. in China has recently received the "Acceptance Notice" from the State Food and Drug Administration.
https://finance.eastmoney.com/
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Baili Tianheng’s revenue is expected to increase by 932% January 30, 2025
- Promoting the “going out” of medicines, my country opens up the “next stop” of medicine centralized procurement for ASEAN January 30, 2025
- Fosun Pharma’s drug registration application for salbutamol hydrochloride has been accepted January 30, 2025
- encourage and support pharmaceutical operators to strengthen anti-monopoly compliance January 30, 2025
- Johnson & Johnson’s revenue increased by 4.3% to US$88.821 billion last year, and pharmaceutical sales increased by 5.8% January 30, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
